Mercury Biopharmaceutical Corporation (TPEX:6932)
Taiwan · Delayed Price · Currency is TWD 9.59
+0.71 (8.00%)
Jul 16, 2025, 1:58 PM CST
Mercury Biopharmaceutical Company Description
Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan.
The company develops StackDose platform, a drug development platform to produce new dosage forms with precise time-controlled dissolution, precise site absorption, and various dosage adjustments to enhance the bio-availability of active pharmaceutical ingredients to reduce the dosage of drugs and its side effects.
It develops drugs for treating erectile dysfunction, pulmonary hypertension, sleep disorder, benign prostatic hyperplasia, angina pectoris, migraine, anti-hypertension, and analgesic.
The company was founded in 2019 and is based in New Taipei City, Taiwan.
Mercury Biopharmaceutical Corporation
| Country | Taiwan |
| Founded | 2019 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Yaoren Liang |
Contact Details
Address: 15th Floor New Taipei City Taiwan | |
| Phone | 886 2 8221 2020 |
| Website | merdury.com |
Stock Details
| Ticker Symbol | 6932 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006932007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yaoren Liang | GM and Director |
| Chun Chun Zhang | Vice President of Administration and Accounting Supervisor |
| Ruixing Chen | Legal Director and Director |
| Nanxiong Zhang | Chief Marketing Officer and Director |